How to Get Wegovy in New Hampshire

What Is Wegovy and Why Does It Work?

Wegovy is the brand name for semaglutide 2.4 mg, a GLP-1 receptor agonist approved by the FDA in June 2021 specifically for chronic weight management. It mimics the incretin hormone GLP-1, slowing gastric emptying, reducing appetite signaling in the hypothalamus, and improving glycemic control. The drug is not a short-term diet aid. It is prescribed as an adjunct to a reduced-calorie diet and increased physical activity.

The landmark STEP-1 trial (N=1,961) demonstrated that participants receiving semaglutide 2.4 mg lost a mean of 14.9% of their body weight over 68 weeks, compared with 2.4% in the placebo group [1]. That difference was statistically significant (P<0.0001). Roughly one-third of the semaglutide group achieved ≥20% weight loss, a threshold previously associated only with bariatric surgery outcomes [1].

The STEP-2 trial focused on adults with type 2 diabetes and obesity, showing 9.6% mean weight reduction at 68 weeks versus 3.4% with placebo [2]. These results positioned semaglutide 2.4 mg as the most effective single-agent GLP-1 therapy for weight loss available at the time of its approval.

For New Hampshire patients, the clinical profile matters because insurers and prior authorization reviewers reference these trial endpoints when evaluating coverage requests.

Who Can Prescribe Wegovy in New Hampshire?

Any physician (MD or DO), nurse practitioner (APRN), or physician assistant (PA) holding an active New Hampshire license can prescribe Wegovy. NPs in New Hampshire practice under full practice authority per RSA 326-B, meaning they do not require a collaborative agreement with a physician to prescribe Schedule III-V controlled substances or non-controlled prescription medications like semaglutide.

This is a practical advantage. Patients in rural parts of the state, including Coos County and portions of Grafton County where endocrinologists and obesity medicine specialists are scarce, can see a local NP or PA for their prescription. The Endocrine Society's 2023 clinical practice guideline on pharmacologic management of obesity recommends that "all clinicians who manage patients with obesity should be prepared to prescribe anti-obesity medications," not just subspecialists [3].

If you already have an established relationship with a primary care provider in New Hampshire, that clinician can write the prescription, order the required labs, and submit the prior authorization. No referral to an endocrinologist or bariatric specialist is needed.

Telehealth Access for Wegovy in New Hampshire

New Hampshire permits telehealth prescribing for Wegovy. State law allows licensed providers to establish a patient-provider relationship via a synchronous audio-video visit without requiring an in-person encounter first. This means a New Hampshire resident in Berlin, Keene, or Lebanon can receive a Wegovy prescription from a telehealth platform without driving to Manchester or Concord.

Telehealth obesity medicine visits typically follow this workflow:

1. Complete a medical intake form documenting BMI, weight history, comorbidities, and current medications.
2. Upload or provide recent lab results (within 90 days in most cases).
3. Attend a synchronous video consultation with a licensed prescriber.
4. Receive an electronic prescription sent directly to your chosen pharmacy.

The American Telemedicine Association has endorsed telehealth as appropriate for ongoing management of chronic conditions, including obesity, provided that standard-of-care assessments are performed [4]. For Wegovy specifically, this includes baseline labs, a cardiovascular risk screen, and documentation that the patient meets BMI criteria.

Turnaround times vary. Some telehealth platforms complete the prescriber visit within 48 hours of intake. Pharmacy fulfillment adds 3 to 7 business days for mail-order delivery within New Hampshire. Patients selecting a local retail pharmacy (CVS, Walgreens, or an independent pharmacy) may pick up the medication the same day the prescription is processed, assuming stock is available.

Lab Requirements Before Starting Wegovy

Most prescribers in New Hampshire require baseline labs before writing a Wegovy prescription. These labs serve two purposes: confirming eligibility and establishing a safety baseline. A standard pre-Wegovy panel includes:

• Comprehensive metabolic panel (CMP): Assesses kidney function (eGFR, creatinine) and liver enzymes (ALT, AST). Semaglutide is not recommended in patients with severe renal impairment (eGFR <15 mL/min) per the FDA prescribing information [5].
• Lipid panel: Baseline LDL, HDL, and triglycerides to track cardiometabolic improvement.
• HbA1c or fasting glucose: Rules out undiagnosed type 2 diabetes and guides dose selection if diabetes is present.
• Thyroid function (TSH): Semaglutide carries a boxed warning regarding thyroid C-cell tumors observed in rodent studies. While human relevance is uncertain, the FDA label states it is "contraindicated in patients with a personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2" [5].

Labs can be drawn at any Quest Diagnostics, Labcorp, or hospital-affiliated draw station in New Hampshire. Many telehealth platforms provide a lab order that patients can take to a local facility. Results are typically available within 1 to 3 business days.

Some prescribers also request a baseline body composition measurement and waist circumference, though these are clinical assessments rather than lab draws.

Insurance and Prior Authorization in New Hampshire

Insurance coverage for Wegovy in New Hampshire depends on the plan type. Here is the breakdown.

Commercial insurance: Most major commercial plans (Anthem Blue Cross Blue Shield NH, Cigna, Harvard Pilgrim, and Aetna) include Wegovy on their formularies, but nearly all require prior authorization. The prior authorization process demands documentation of:

• BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea)
• Previous failed attempts at lifestyle modification (diet and exercise), typically documented over a minimum of 3 to 6 months
• In some cases, a failed trial of an alternative anti-obesity medication (phentermine, orlistat, or naltrexone-bupropion)

The American Association of Clinical Endocrinology (AACE) 2023 consensus statement describes prior authorization requirements for anti-obesity medications as "a barrier to evidence-based care that disproportionately delays treatment for patients with severe obesity" [6].

NH Medicaid: New Hampshire Medicaid does not cover Wegovy for chronic weight management as of 2026. Patients on Medicaid may explore manufacturer savings programs or 503A compounding pharmacy options as alternatives.

Medicare Part D: Traditional Medicare Part D did not cover anti-obesity medications historically. The Treat and Reduce Obesity Act has been introduced in multiple congressional sessions to change this, but coverage remains limited. Some Medicare Advantage plans in New Hampshire have added GLP-1 coverage for weight management. Check with your specific plan.

Novo Nordisk savings program: Eligible commercially insured patients may pay as little as $0 to $25 per 28-day supply through the Wegovy savings card. Uninsured patients and those whose insurance does not cover the drug face a list price of approximately $1,349 per month.

503A Compounding Pharmacy Access in New Hampshire

New Hampshire permits licensed 503A compounding pharmacies to prepare and dispense compounded semaglutide formulations. A 503A pharmacy compounds medications based on individual patient prescriptions, as regulated under Section 503A of the Federal Food, Drug, and Cosmetic Act.

Key points for NH patients considering compounded semaglutide:

• The prescriber must write a patient-specific prescription. Bulk manufacturing by 503A pharmacies is not permitted.
• Compounded semaglutide is not FDA-approved Wegovy. It uses the same active pharmaceutical ingredient but may differ in formulation, concentration, and delivery device.
• The FDA has issued safety communications cautioning that compounded versions have not undergone the same testing for safety, efficacy, and quality as approved products [7].
• Cost for compounded semaglutide typically ranges from $150 to $500 per month, significantly less than brand Wegovy.

Patients choosing this route should confirm their pharmacy holds a valid New Hampshire Board of Pharmacy compounding license and follows USP 797 sterile compounding standards.

Dose Escalation and What to Expect

Wegovy follows a fixed 16-week dose escalation schedule designed to minimize gastrointestinal side effects:

| Weeks | Dose | |-------|------| | 1 to 4 | 0.25 mg weekly | | 5 to 8 | 0.5 mg weekly | | 9 to 12 | 1.0 mg weekly | | 13 to 16 | 1.7 mg weekly | | 17 onward | 2.4 mg weekly (maintenance) |

The most common side effects during escalation are nausea, vomiting, diarrhea, and constipation. In STEP-1 to 44.2% of participants in the semaglutide group reported nausea, though most episodes were mild to moderate and decreased after the first 8 to 12 weeks [1]. Discontinuation due to gastrointestinal events occurred in 4.5% of the semaglutide group versus 0.8% in the placebo group [1].

Weight loss is typically not dramatic during the first 4 to 8 weeks at the lower doses. Clinically meaningful results begin appearing around weeks 12 to 16. The STEP-1 trial showed that weight loss continued through week 60 before plateauing, with 86.4% of semaglutide-treated participants achieving ≥5% weight loss [1].

Dr. Robert Kushner, a professor of medicine at Northwestern University Feinberg School of Medicine and investigator in the STEP program, has noted: "The dose-escalation schedule is not optional. Skipping steps to reach the maintenance dose faster increases the risk of severe nausea and treatment discontinuation" [8].

Transferring a Prescription to New Hampshire

Patients who move to New Hampshire or split time between states can transfer an existing Wegovy prescription. The process depends on where the original prescription was written.

For prescriptions from another U.S. state, the receiving New Hampshire pharmacy can process an interstate prescription transfer. The New Hampshire Board of Pharmacy permits transfers of non-controlled prescriptions between states, and semaglutide is not a controlled substance. The pharmacist at your NH pharmacy contacts the originating pharmacy to complete the transfer.

If you are using a telehealth platform, confirm that the prescribing provider holds a New Hampshire license. Some multistate telehealth companies are licensed in New Hampshire already. Others may need to transfer your care to an NH-licensed prescriber within their network.

Patients should also verify that their insurance plan covers pharmacy fills in New Hampshire, particularly if they are on an out-of-state employer plan with a narrow pharmacy network.

Timeline: From First Click to First Injection

A realistic timeline for a New Hampshire patient starting Wegovy through telehealth:

• Day 1: Complete online intake and submit medical history.
• Days 2 to 3: Lab order received; labs drawn at local facility.
• Days 4 to 6: Lab results returned; video visit with prescriber.
• Days 6 to 8: Prescription submitted; prior authorization initiated if insurance is used.
• Days 8 to 21: Prior authorization review (commercial insurers average 5 to 14 business days).
• Days 21 to 28: Medication shipped or available at pharmacy.

Without prior authorization (cash pay or using a 503A pharmacy), the timeline compresses to approximately 7 to 14 days from intake to first injection. The longest variable is the prior authorization process, which the AACE has identified as adding a median of 10 business days to treatment initiation for GLP-1 receptor agonists [6].

Monitoring and Follow-Up in New Hampshire

After starting Wegovy, follow-up visits are typically scheduled at 4 weeks, 12 weeks, and then every 3 months. Telehealth platforms can handle most follow-up visits remotely. The prescriber will monitor:

• Weight and BMI trajectory
• Side effect profile and tolerability
• Blood pressure and heart rate (semaglutide can increase resting heart rate by 1 to 4 beats per minute per the FDA label) [5]
• Repeat labs at 3 and 6 months (CMP, lipid panel, HbA1c if diabetic)

The SELECT trial (N=17,604), published in 2023, demonstrated that semaglutide 2.4 mg reduced the risk of major adverse cardiovascular events (MACE) by 20% in adults with overweight or obesity and established cardiovascular disease, independent of diabetes status [9]. This finding led to an expanded FDA indication for cardiovascular risk reduction, which may affect insurance coverage decisions and prior authorization criteria in New Hampshire going forward.

Patients who do not achieve ≥5% weight loss after 6 months on the maintenance dose of 2.4 mg should discuss treatment options with their prescriber, as the FDA label recommends considering discontinuation in non-responders [5].